Siga’s Monkeypox Drug to Start Human Testing in September

Siga Technologies Inc.’s Tpoxx, a monkeypox treatment stockpiled by the US, will undergo its first rigorous human test in a trial slated to open as soon as September.

Tpoxx, already approved for smallpox treatment in the US, has expanded access clearance for monkeypox based mainly on data from animal studies. A National Institute of Allergy and Infectious Diseases-run study is one of three about to begin that will generate much-needed data that US regulators will use to determine whether Tpoxx should get full approval to treat monkeypox, Siga Chief Scientific Officer Dennis Hruby said in an interview.

“There’s been ...